Purpose: To determine incidence, risk factors, risk period, and characteristics of recurrent retinopathy of prematurity (ROP) treated by intravitreal bevacizumab (IVB) monotherapy.
eye. Especially in zone 1 cases and when near confluent laser therapy is performed, unavoidable consequences occur frequently, with clinical implications including loss of visual field, 13 increased myopia, 14 and development of late angleclosure glaucoma. 15, 16 Other potential complications of laser therapy include posterior synechiae, irregular pupils with inability to dilate completely, cataracts, development of early angle-closure glaucoma, phthisis, leakage from choroidal vessels, and retinal detachment. Most of these consequences and complications (especially the increased myopia 17e20 related to altered anterior segment development) 19, 20 may be decreased by IVB monotherapy. 21 The Cryotherapy for Retinopathy of Prematurity 2 and Early Treatment for Retinopathy of Prematurity 3 studies both suggest that recurrence after peripheral retinal ablation for type 1 ROP generally occurs before 54 weeks adjusted age (AA). However, IVB causes a delay in retinal vascularization, which is especially concerning if recurrence develops. 22 The appropriate time to perform and to suspend follow-up examinations to allow timely diagnosis and treatment of recurrence after IVB monotherapy must be structured properly and extended until retinal vascularization is considered complete, 22 which may not necessarily reach the ora serrata in the most immature infants. 23, 24 Cases of late recurrence after anti-VEGF monotherapy or combined with laser therapy have been reported in the literature with seemingly minimal lapses in follow-up. Thus, the apprehension of not knowing how frequently recurrence occurs (incidence of recurrence), which infants are at greatest risk for recurrence (risk factors), when the period of risk for recurrence finally ends (risk period), and where in the retina to concentrate follow-up examinations (clinical characteristics) causes many physicians to be very hesitant to treat ROP with IVB monotherapy.
Methods
Two cohorts were reviewed in this large retrospective case series: 75 infants treated with IVB in the BEAT-ROP clinical trial (Clinicaltrials.gov trial identifier, NCT00622726) from March 13, 2008 , through August 4, 2010, 12 and 218 infants treated consecutively with IVB (by H.M.H.) after the BEAT-ROP clinical trial who were treated and followed up at the Memorial Hermann Hospital System, Houston, Texas, and at the hospitals in Webster, Corpus Christi, and El Paso, Texas, from August 5, 2010, through December 31, 2014 . The Committee for the Protection of Human Subjects (the Institutional Review Board at The University of Texas Health Science Center) approved the study. All research adhered to the tenants of the Declaration of Helsinki and complied with the Health Insurance Portability and Accountability Act.
All infants received IVB monotherapy for type 1 ROP in zone I or zone II posterior with plus disease (published in the Early Treatment for Retinopathy of Prematurity study 3 in 2003), subdivided in this study into stage 3þ ROP and aggressive posterior ROP (APROP; included in the International Classification of ROP Revisited 25,26 in 2005) . Stage 3þ disease was defined as "extraretinal fibrovascular proliferation (EFP) or neovascularization that went through stages 1 and 2 to 3 that extends from the ridge into the vitreous," and APROP was defined as an aggressive form of ROP typically seen in the posterior pole vessels that "show[s] increased dilation and tortuosity in all 4 quadrants that is out of proportion to the peripheral retinopathy" and "may appear as only a flat network of neovascularization at the deceptively featureless junction between vascularized and nonvascularized retina" (as defined by the International Classification of ROP-Revisited). 25, 26 All infants included in the study and its analysis underwent follow-up examinations extending to 65 weeks. All infants were treated with IVB monotherapy using the standard protocol as described in the BEAT-ROP clinical trial. 12 Both the first (initial treatment for type 1 ROP) and the second (treatment for recurrence of type 1 ROP) IVB injections given to patients were the same dose (0.625 mg; 0.025 ml). All bilateral treatments and re-treatments were performed on the same day, rather than as a staged procedure. RetCam fundus photography (Clarity Medical Systems, Inc, Pleasanton, CA) was used before the first IVB injection in all infants (n ¼ 241) to document type 1 ROP, before the second IVB injection in all infants (n ¼ 20) with recurrent ROP to document recurrence characteristics, and during follow-up as needed for clinical management. Fluorescein angiography was performed on infants (n ¼ 9) at the time of recurrence and, when possible, to document the final extent of retinal vascularization in infants with and without recurrence. The final extent of retinal vascularization was measured, and the rate of retinal vascularization was calculated in eyes without (n ¼ 25) and with (n ¼ 25) recurrence. The nonrecurrent eyes were selected from the 104 nonrecurrent eyes of the BEAT-ROP clinical trial because these had been photographed (as per protocol) at the time of initial treatment and at approximately 54 weeks. 12 Zone I ROP cases were selected to be measured so that final extent was clear. The final extent of zone II ROP cases was not always clear and measurable. The recurrent eyes were selected from 34 eyes (recurrences from both cohorts, the 6 recurrent eyes of BEAT-ROP clinical trial and the 28 recurrent eyes after the end of that clinical trial that were treated with bevacizumab monotherapy). Of these 34 eyes, 18 had ROP in zone I initially and 16 had ROP zone II initially. The zone I and II eyes with the clearest final extent were selected to be measured. The selected photographs were printed and assembled from the optic nerve through the macula to the advancing edge. The disc diameter (DD) was measured. This measurement was used to calculate the extent of progression of retinal vascularization from the initial treatment site to the final extent of the retina in DDs (nonrecurrent eyes) or from the initial to the second treatment sites in the retina in DDs (recurrent eyes). Dates of the photographs were used to calculate the rate of progression of retinal vascularization.
The study unit for all data analyses was infant, not eye; thus, any unilateral recurrence was considered a recurrence. Any infants with asymmetric zones of ROP between the 2 eyes were classified as the smallest of the 2 zones. Demographic and baseline clinical data were summarized by mean AE standard deviation for continuous variables or frequency (percentage) for discrete variables. Univariate analysis, the 2-sample t test, or the Fisher exact test was used to compare each demographic, health status, and characteristic of initial treatment variable between infants without and with recurrence. Because of the correlation among the potential risk factors, a multivariate analysis with bidirectional stepwise logistic regression was used to identify and assess any potential risk factors for recurrence of ROP, including birth weight (BW), gestational age (GA), Apgar score at 1 and 5 minutes, initial location of ROP (zone I or zone II posterior), initial appearance of type 1 ROP (subdivided into stage 3þ ROP or APROP), duration of hospital stay, and other systemic conditions including necrotizing enterocolitis (NEC) requiring surgery, sepsis proven by positive blood culture results, patent ductus arteriosus requiring surgery, and intraventricular hemorrhage. The odds ratio and associated P value (with P < 0.05 indicating significance) for each risk factor were determined. All statistical analyses were performed using SAS for Windows version 9.4 (SAS, Inc, Cary, NC).
The characteristics of ROP were recorded at the first treatment (for initial type 1 ROP) and the second treatment (for recurrent ROP, whether unilateral or bilateral) as follows:
1. At first (initial) treatment, type 1 ROP (stage 3þ ROP or APROP), the location (zone) of the ROP, and the timing of the development of ROP (as postnatal age and as AA ¼ GA þ postnatal age) were recorded. 2. At second (recurrent) treatment, the site of reappearance of neovascularization at the advancing edge and at the original site of the ridge and EFP complex (RþEFP) with return of plus disease, the location (zone: now distance from original location of ROP) of the advancing edge of retinal vascularization, and the timing (postnatal age and AA) of the recurrence of ROP and the interval between treatments (in weeks) were recorded. 3. The number of weeks from the initial treatment to the last follow-up examination and AA at the last follow-up examination for all infants (without or with recurrence) also were recorded. 4. Fundus photographs and fluorescein angiograms were reviewed to observe the location of neovascular changes at first treatment (for initial type 1 ROP), at second treatment (for recurrent ROP), and after stabilization of these changes as follows. In a sample of eyes either with or without recurrence, the extent of retinal vascularization at the first treatment with IVB was measured in DDs (measured from the temporal edge of the optic nerve through the fovea to the advancing edge by M.M.G.). In those eyes with recurrence, the extent of vascularization at the location of the second treatment for recurrence was measured in the number of DDs (by M.M.G.). The difference between the first and second IVB treatments (exact dates used) was calculated as the extent of progression of retinal vascularization. In those eyes without recurrence, the extent of vascularization at their location at 54 weeks AA was measured in DDs, as it was for part of the initial BEAT-ROP protocol 12 (by M.M.G.). The difference between IVB treatment and the extent of vascularization at 54 weeks AA (exact dates used) was calculated as the extent of progression of retinal vascularization. The rate of vascular progression for eyes with recurrence then was calculated by the number of DDs of radial progression between the first and second IVB treatments divided by number of weeks between the IVB treatments (exact dates used). The rate of vascular progression for eyes without recurrence then was calculated by the number of DDs of radial progression between the IVB treatment and 54 weeks AA divided by the number of weeks between the IVB treatment and 54 weeks AA (exact dates used). Any difference in extent of vascular progression (in number of DDs) or in rate of vascular progression (in number of DDs per week) between eyes with or without recurrence was evaluated by a mixed-effect model. In the model, the subject unit was the infant, the correlation structure between eyes was the compound symmetric, and the fixed effect was without and with recurrence.
Results
A total of 241 infants (471 eyes, i.e., 11 unilateral cases) treated with IVB monotherapy for ROP in zones I or II posterior were eligible for review in this study (55 infants from the BEAT-ROP clinical trial and 186 infants treated after the BEAT-ROP clinical trial). Thirty-one infants without follow-up examinations extending to 65 weeks were excluded from analysis, as well as 21 infants who had died before 65 weeks.
The demographics, infant characteristics, and initial treatment information are summarized for all infants and subdivided between those without and with recurrence ( Table 1 ). The recurrences were subdivided further between those with stage 3þ ROP and APROP at initial treatment (Table 1) . Of all 241 study infants, the average BW was 714AE200 g (95% confidence interval [CI], 340e1590 g); the average GA was 24.7AE1.7 weeks (CI, 22e32 weeks); 131 infants (54.4%) were male; and 136 infants (56.4%) were Hispanic. Most of the infants (n ¼ 230 [95.4%]) had bilateral ROP; 222 infants (92.1%) had stage 3þ ROP, and 181 infants (75.1%) had ROP in zone II posterior (all stage 3þ ROP), whereas 60 infants (24.9%) had ROP in zone I (41 with stage 3þ ROP and 19 with APROP). The average AA at the initial treatment was 35.9AE2.6 weeks (CI, 31e49 weeks). These 241 infants were followed up after the initial treatment for an average of 132.6AE90.2 weeks (CI, 19e384 weeks), with the last followup examination at an average of 168.5AE89.9 weeks AA (CI, 66e417 weeks AA). For those without recurrent ROP, the average follow-up was 131.2AE89.7 weeks (CI, 19e370), whereas for those infants with recurrent ROP, the average follow-up was 148.4AE95.9 weeks (CI, 39e384 weeks).
Incidence of Recurrence
Twenty of 241 infants (8.3%) with 34 of 471 eyes (7.2%) had recurrent ROP (see Table 1 ). Figure 1 shows the Kaplan-Meier survival curve subdivided by initial appearance (stage 3þ ROP compared with APROP). Infants treated for APROP had significantly greater recurrences after initial treatment (31.6% recurrence incidence in those with APROP vs. 6.3% recurrence incidence in those with stage 3þ ROP; P < 0.001). Details of recurrence for each infant are given in Table 2 .
Risk Factors for Recurrence
Six baseline characteristics, including immaturity factors (BW [P < 0.001], GA [P < 0.001], and zone [P ¼ 0.003]), initial treatment appearance (APROP [P ¼ 0.002]), and health risk factors (single risk factor of NEC [P ¼ 0.035] and cumulative health issues noted by duration of hospitalization [P < 0.001]), were significantly different between infants without and with recurrence of ROP (see Table 1 ).
Infants with ROP recurrence were significantly more immature at birth than those without ROP recurrence. Average BW of recurrent ROP infants (600AE113 g) was significantly lower than that of the nonrecurrent ROP infants (724AE203 g; P < 0.001). Average GA was significantly lower in the recurrent ROP group (23.9AE0.9 weeks) compared with the nonrecurrent ROP group (24.8AE1.8 weeks; P < 0.001). Eleven of 60 zone I infants recurred (18.3%), whereas 9 of 181 zone II posterior infants (5.0%) recurred (P ¼ 0.003). Additionally, in the recurrent ROP infants, the BW of APROP infants (512AE73 g) was significantly lower than that of the stage 3þ ROP infants (638AE107 g; P ¼ 0.017).
The results of stepwise logistic regression analysis with bidirectional elimination of all clinical and demographic data identified 3 risk factors for recurrent ROP developing: the initial type1 ROP appearance of APROP (P ¼ 0.006), increased duration of hospital stay (P ¼ 0.010), and decreased BW (P ¼ 0.024). Infants initially treated for APROP were found to have a 5-fold increased risk of recurrent disease developing than those infants treated for stage 3þ ROP (95% CI, 1.59e16. 4 ). An average of a 1-week increase in Table 2 ). Patient 5 demonstrated a stage 4A ROP temporal retinal detachment in the right eye and received a second IVB injection with final outcome of macular dragging, but resolution of the stage 4A ROP detachment. Patient 13 returned for follow-up with stage 5 ROP in the right eye and stage 4B ROP in the left eye and was referred for vitrectomies, which were unsuccessful. The patient did not receive a second injection of IVB ( Table 2) . Both of these patients were detailed previously in the BEAT-ROP clinical trial. 12 Table 2 ). However, 6 of 6 infants (100%; and 8/8 eyes [100%]) with APROP recurred only at the advancing edge. After the second IVB treatment, plus disease did not decrease, but neovascularization resolved in all cases.
Clinical Characteristics of Recurrence
A third characteristic of recurrence was a decreased extent of retinal vascularization as evidenced by progression of the advancing edge only a mean of 1.76AE1.0 DD (CI, 0.48e4.75 DD; n ¼ 25 eyes) from its location at the time of initial treatment compared with that at the time of recurrence. This was significantly less (P ¼ 0.024) than the extent of progression of retinal vascularization seen in eyes without recurrence, with a mean of 4.48AE1.46 DD (CI, 1.41e7.60 DD; n ¼ 25 eyes). Similarly, there was also a significantly decreased rate of retinal vascularization in eyes with ROP recurrence, with a mean of 0.11AE0.05 DD/week (CI, 0.03e0.20 DD/week; n ¼ 25 eyes) versus in those without ROP recurrence, with a mean of 0.23AE0.07 DD/week (CI, 0.07e0.36 DD/week; n ¼ 25 eyes; P ¼ 0.032). Figure 2C , D shows an eye that recurred and required a second injection to induce regression for stage 3þ ROP with 2 recurrence sites. Figure 3C , D shows an eye that recurred and required a second injection for APROP with 1 recurrence site. Figure 4A , B shows an eye that required only 1 injection to induce regression for stage 3þ ROP. Figure 4C , D shows an eye that required only 1 injection to induce regression for APROP. Figure 4E , F shows an eye that required no injection (for stage 2 ROP) and regressed spontaneously, for comparison. These 5 infants (Figs 2e4) were selected because they had similar BW (range, 450e510 g) and GA (range, 23e24 weeks).
Discussion
There have been several case reports of late recurrence after treatment of stage 3þ ROP or APROP with IVB monotherapy 27, 28 and after combined treatment using laser therapy with intravitreal ranibizumab 29 or with IVB. 27,30e32 In each of these reports, close follow-up (every 1 or 3 weeks) was not performed beyond 55 weeks AA; however, standard follow-up recommendations have not been established by ophthalmologic studies reviewing prospective data. Also, not surprisingly, there are reports of failure after use of IVB monotherapy for ROP stages 4B and 5 because treatment was performed too late and membrane formation was too extensive. 33e35 Of greatest interest in the literature is a case series of 9 patients (17 eyes) treated initially with IVB monotherapy for stage 3þ ROP or APROP at a mean of 34.1 weeks AA with recurrences developing at mean of 49.3 weeks AA. Thus, they found an interval between initial IVB monotherapy and recurrence with a mean of 15.2 weeks. 22 The authors of this case series discussed the return of plus disease and the reappearance of neovascularization at 1 or 2 sites: at the RþEFP, at the advancing edge of retinal vascularization, or both. This is identical to our findings.
From these previous reports of recurrence and the results of this study, several clinical management issues can be recognized. Intravitreal bevacizumab monotherapy is a very effective recent addition to the treatment armamentarium for ROP, with less than 8% incidence of recurrence in infants or eyes requiring a second IVB treatment. There is only 1 case series from Turkey reporting the need for a third injection of IVB 36 ; however, there are no published cases of infants requiring a third administration of IVB in developed nations, to our knowledge. If an infant has identified risk factors (APROP at the time of initial treatment, extended duration of hospitalization because of multiple clinical risk factors, or very low BW), this should cause clinicians to be more vigilant and to examine them more frequently and possibly longer. Clinical characteristics of return of plus disease and reappearance of neovascularization (at the original site of the ridge and extraretinal fibrovascular proliferative complex, at the advancing edge of retinal vascularization 22 [as well as at other currently unknown sites], or both) are required to diagnose the need for re-treatment of recurrent type 1 ROP after IVB monotherapy. Additionally, a small extent and a slow rate of advancement of retinal vascularization is noted (Figs 2 and 3) , which is especially notable in zone I cases, and should be considered a warning sign of possible imminent recurrence. When an infant initially was treated for stage 3þ ROP with confluent EFP, recurrence was observed and documented at 2 distinct sites: at the original RþEFP site and at the advancing edge of retinal vascularization (Fig 2) . In comparison, when an infant initially was treated for APROP or stage 3þ ROP with only nonconfluent EFP, recurrence was observed and documented at only 1 site: at the advancing edge of retinal vascularization (Fig 3) . Although the location of the neovascularization could be seen with the indirect ophthalmoscope with a 20-or 28-diopter lens and with fundus photography, it was best documented by fluorescein angiography with the RetCam imaging system ( Fig  2C, D and Fig 3C, D) . Although we were unable to perform fluorescein angiography in all cases of recurrence, based on the photographs obtained in all cases of recurrence and the available fluorescein angiograms (9 infants), it is our impression that Figures 2 and 3 are representative of the 2 common patterns of recurrence.
Because there is a virtual cessation of retinal vessel advancement after the second IVB injection, there is often a large avascular peripheral area of retina that remains undeveloped, especially in former zone I and APROP cases. Successful IVB treatment (inducing regression of ROP) usually is recognized before 65 weeks AA by a rapid advancement of retinal vascularization from the original RþEFP in stage 3þ ROP (Fig 4A, B) or from the original flat network of neovascularization in APROP (Fig 4C, D) toward, but not necessarily to, the ora serrata in the most immature infant eyes. 23, 24 Anecdotally, spontaneous regression of ROP also is accompanied by rapid advancement of retinal vascularization before 65 weeks AA (Fig 4E,  F) toward, but not necessarily to, the ora serrata in the most immature infant eyes. 23, 24 In all cases of regressed ROP, whether after 2, 1, or no IVB injections, it is our experience and belief that, unless extensive tractional elements are present, no further intervention, such as laser ablation, is indicated for the remaining permanently undifferentiated, peripheral, avascular retina.
Timing of the administration of IVB monotherapy is critical. Intravitreal bevacizumab is an ideal treatment when ocular (and blood) VEGF levels are high with sufficient neovascularization (phase 2), rather than when VEGF levels are low with minimal neovascularization (before phase 2). 37 Intravitreal bevacizumab can inhibit normal development of the retina if administered in phase 1, and thus IVB cannot be used as prophylactic treatment. 37 Similarly, IVB is administered ideally before the development of advancing retinal detachment (after phase 2), as has been demonstrated by reports of accelerated retinal detachment after IVB treatment for ROP stages 4B and 5.
33e35 Therefore, IVB cannot be used as salvage therapy. This is the clinical experience in diabetic patients who demonstrate accelerated retinal detachment associated with IVB administration when tractional membranes are extensive. 38 Appropriate follow-up examinations are mandatory for successful clinical management. Recurrence of ROP after IVB monotherapy now should be identifiable more easily and promptly by treating ophthalmologists. Because the incidence of recurrence is less than 8%, most infants will demonstrate regression with rapid progression of retinal vessels toward the ora serrata. The risk factors for recurrence are known to be immaturity (lower BW and GA and zone 1 ROP), APROP, and cumulative health issues (i.e., duration of hospital stay and NEC requiring surgery), which should heighten vigilance during follow-up examinations. The risk period of recurrence of ROP after IVB, although more delayed, is predictable with a critical 10-week recurrence window from approximately 45 to 55 weeks AA, with recurrence developing at a mean of 51.2 weeks AA and, infrequently, as late as 65 weeks AA, as shown by this series of recurrences. We believe collaborative consensus groups should consider amending the current guidelines of weekly examinations until 70 weeks AA 39 in light of the knowledge of this report to reflect the available evidence better. We believe clinicians should be more vigilant in their examinations for recurrence during the 45-to 55-week AA recurrence window and should perform more frequent examinations during this time. Before and after this critical period, we believe examinations can be less frequent until retinal vascularization is completed. However, we believe those initially treated for APROP are at increased risk for recurrence and should be monitored closely until at least 65 weeks AA (as was the case of the delayed recurrences in this series).
There are several appearances of regressing ROP in the first few weeks after initial treatment with IVB, with the retinal vessels ranging from the appearance of vascular projections from the former RþEFP without a defined new ridge to an advancing edge with a defined ridge that may thicken. However, clinicians easily can distinguish these normal regression patterns from recurrence of ROP by the continued resolution of plus disease and the lack of continued progression of formation of dilated, hyperemic vessels (neovascularization) in the former RþEFP. Also, the appearance of these regression patterns often is much earlier than the period in which recurrence usually occurs (approximately 45e55 weeks AA). Furthermore, it is our clinical impression from anecdotal experience that after treatment with IVB, the plus disease resolves rather quickly, that is, within a couple of days, whereas the RþEFP can take several weeks to resolve, depending on how extensive the neovascularization was before treatment, retreatment, or both. However, it is our clinical impression that this delayed resolution of RþEFP can be discerned from early recurrence by the appearance of closed gray to white vessels at the site of the former RþEFP.
The strengths of this study are the large sample size with all infants following the same examination, documentation, and treatment protocols used in the BEAT-ROP clinical trial and that the same clinical information was available for all of these infants, who were all documented photographically, with last mean follow-up at age 148.1 weeks AA, over a period of almost 7 years.
The limitations of this study are that much of what we now recognize about recurrence has been learned after the initial documentation protocol was designed. Thus, patterns of recurrence were not known from the initial time that IVB monotherapy began to be used for treatment-warranted ROP. Further, fluorescein angiography was not available at some of the centers, and the importance of performing fluorescein angiography at the time of recurrence was not known. Thus, fluorescein leakage at the 2 specific sites with recurrence was not documented for all infants. Fortunately, the changes in the critical sites of recurrence in the retina were observed by indirect ophthalmoscopy and were documented by fundus photography for all recurrences. Further, it would have been ideal to sample prospectively each infant's blood VEGF level before each IVB injection and the bevacizumab blood level for a few months after each IVB injection to establish any relationship to severity of initial disease and to the development of recurrence. Additionally, perhaps the screening and treatment of this study's population with more Hispanic patients than those of other published ROP clinical trials may have influenced the clinical findings to some degree.
As with any treatment involving injection of a drug not approved by the Food and Drug Administration for intravitreal use in premature infants for ROP, further investigation to determine the long-term safety concerns (both ocular and systemic) of IVB monotherapy should be performed systematically. More investigation into the most efficient drug and dose of an intravitreal anti-VEGF drug for ROP also is needed. Ultimately, a higher dose of an ideal anti-VEGF drug may be appropriate for those infants with higher risk of recurrence of ROP after anti-VEGF therapy. Conversely, a lower dose of an ideal anti-VEGF drug may be appropriate for those infants who have lower risk of recurrence of ROP after anti-VEGF therapy.
In summary, IVB is a very effective treatment for ROP. Recurrence is very important to recognize promptly, and infants should be followed up closely until they are beyond the period during which recurrence has been reported. We hope this report can help clinicians feel more comfortable treating with IVB monotherapy and following up patients for recurrence with knowledge that the incidence of recurrence is low (8.3% in this study); that some infants at increased risk for recurrence are identifiable (initial treatment for APROP, multiple ROP risk factors requiring prolonged hospitalization, especially if NEC requiring surgery has occurred, and extremely low BW); that the recurrence risk period is limited, although extended compared with laser therapy, with the vast majority of cases recurring during a critical period (approximately 45e55 weeks AA and before 65 weeks AA); and that with the return of plus disease and lack of progression of retinal vascularization, there are 2 specific locations to reexamine for recurrent neovascularization. With this knowledge, we believe collaborative consensus groups may be able to amend the current screening guidelines to help the clinician monitor for recurrence more safely and efficiently after treatment with IVB.
